Medindia LOGIN REGISTER
Medindia
Advertisement

New Gene Methylation Test for Prostate Cancer Available

Friday, May 16, 2008 General News
Advertisement
RARITAN, N.J., May 16 Veridex, LLC announced today thatits licensing collaborator, Laboratory Corporation of America Holdings(LabCorp), has commercially launched a new gene methylation test for prostatecancer. The new assay uses the biological specificity of 'DNA methylation' inprostate cancer, detecting the methylation of the gene GST-Pi. Methylation isa modification of DNA that occurs primarily in cancer. Veridex is developingthe methylation markers in this tissue assay, GST-Pi, along with othermarkers, for a urine-based screening test for prostate cancer.
Advertisement

Prostate cancer is the leading cause of cancer death in men in the U.S.,with more than 230,000 cases diagnosed annually.

LabCorp licensed the methylation technology from Veridex in 2007. Veridexlicensed this technology from OncoMethylome Sciences, S.A. (OMS).
Advertisement

About Veridex

Veridex, LLC, a Johnson & Johnson company, develops cancer diagnosticproducts that will enable earlier disease detection as well as more accuratestaging, monitoring and therapeutic selection. The company is initiallydeveloping two complementary product lines: CellSearch(TM) assays thatidentify, enumerate and characterize circulating tumor cells directly fromwhole blood; and GeneSearch(TM) assays that use molecular technology todiagnose, stage and more accurately characterize tumors. For additionalinformation, please visit www.veridex.com

SOURCE Veridex, LLC
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close